Drug Profile
Research programme: CD14/TLR4 antagonists - Innaxon
Alternative Names: IAXO small molecules - Innaxon; IAXO-101 - Innaxon; IAXO-102 - InnaxonLatest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator Unknown
- Developer Innaxon
- Class Benzylammonium compounds; Glycolipids; Small molecules
- Mechanism of Action CD14 antigen inhibitors; Toll-like receptor 4 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
Most Recent Events
- 13 Sep 2023 Preclinical development is ongoing in Amyotrophic-lateral-sclerosis in United Kingdom (Innaxon website, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in United Kingdom
- 01 Aug 2016 Preclinical trials in Amyotrophic lateral sclerosis in United Kingdom (unspecified route)